ENCOMPASS HEALTH CORP

Insider selling hits a record pace at Encompass Health—what the CEO’s $21.8 million sale and broader executive exits mean for investors and stock stability.

Encompass Health CFO’s bulk buy at a deep discount signals confidence in a new $500 m debt‑refinance, offering investors a bullish view on stronger balance‑sheet and future returns.

Patrick Tuer’s minor Encompass Health share sale shows a liquidity‑focused trade, not a confidence drop—insider buying, solid fundamentals, and growing rehab services keep the stock on track.

Encompass Health insider trades reveal routine RSU sales, not strategic moves, yet offer insight into executive liquidity and the firm’s focus on value‑based care and tech‑driven growth.

Encompass Health insider sell‑off: CEO Mark Tarr’s block sale highlights portfolio rebalancing, market confidence, and how the company’s tech‑driven, value‑based care strategy may influence future earnings amid shifting reimbursement policies.